BDBM50155810 (R)-3-(6-Methoxy-pyridin-3-yl)-4-[1-(3-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-butyric acid::CHEMBL186206
SMILES COc1ccc(cn1)[C@H](CC1CCN(CC1)C(=O)CCc1ccc2CCCNc2n1)CC(O)=O
InChI Key InChIKey=IKALVLPAIVXDBO-OAQYLSRUSA-N
Data 9 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 9 hits for monomerid = 50155810
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6.10E+3nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.10nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6.10E+3nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair